Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present disclosure relates to the field of formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations.
• United States Patent Application Nos US2010/0310462 and US2009/0092665 disclose drug delivery systems for ophthalmic use that have nanomicelles that include vitamin E TPGS.
• the formulation includes propylene glycol and does not include nanomicelles. HCO-40 is present in Travoprost at 0.5%. See ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000665/WC500038389.pdf on the world-wide web.
• the present disclosure relates to topical formulations such as formulations suitable for ophthalmic administration.
• the formulations of the present disclosure may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles.
• the formulations of the present disclosure are formulated in the absence of any pharmaceutically active agent, i.e., without any non-lipid non-surfactant pharmaceutically active agent that has received regulatory approval for the treatment of an ocular condition.
• formulation is not meant to imply that the ingredients or components are in combination with a pharmaceutically active agent, i.e., any non-lipid non-surfactant active agent that has received regulatory approval for the treatment of an ocular condition.
• formulations as described herein may have certain surprising features and advantages that could not have been predicted prior to the present disclosure.
• the formulations of the present disclosure are surprisingly stable at high temperatures, for example, temperatures above about 40° C.
• the nanomicellular nature of some formulations described herein allow for improved ocular tissue distribution.
• formulations as described herein are particularly suitable for anterior eye delivery, or posterior eye delivery, or anterior and posterior eye delivery.
• a formulation that includes a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol, and does not include an active agent.
• the formulations include nanomicelles.
• the polyoxyl lipid or fatty acid is a polyoxyl castor oil.
• the polyoxyl lipid or fatty acid is one or more selected from HCO-40, HCO-60, HCO-80 or HCO-100.
• the polyoxyl lipid or fatty acid (such as a polyoxyl castor oil such as HCO-40, HCO-60, HCO-80 or HCO-100) is present between 1 and 6%; or 2 and 6%; or 2 and 6%; or 3 and 6%; or 4 and 6%; or 2 and 5%; or 3 and 5%; or 3 and 5%; or 2 and 6%; or about 4%; or greater than 0.7%; or greater than 1%, or greater than 1.5%; or greater than 2%; or greater than 3%; or greater than 4% by weight of the formulation.
• the polyoxyl lipid is HCO-60.
• the polyoxyl lipid is HCO-80.
• the polyoxyl lipid is HCO-100.
• the formulation includes a polyalkoxylated alcohol that is octoxynol-40.
• the formulation includes a polyalkoxylated alcohol (such as octoxynol-40) present between 0.002 and 4%; or between 0.005 and 3%; or 0.005 and 2%; or 0.005 and 1%; or 0.005 and 0.5%; or 0.005 and 0.1%; or 0.005 and 0.05%; or 0.008 and 0.02%; or about 0.01% by weight of the formulation.
• polyoxyl lipid or fatty acid refers to mono- and diesters of lipids or fatty acids and polyoxyethylene diols. Polyoxyl lipids or fatty acids may be numbered (“n”) according to the average polymer length of the oxyethylene units (e.g., 40, 60, 80, 100) as is well understood in the art.
• n 40 polyoxyl lipid means that the ployoxyl lipid or fatty acid has an average oxyethylene polymer length equal to or greater than 40 units.
• Stearate hydrogenated castor oil and castor oil are common lipids/fatty acids commercially available as polyoxyl lipids or fatty acid, however, it is understood that any lipid or fatty acid could polyoxylated to become a polyoxyl lipid or fatty acid as contemplated herein.
• polyoxyl lipid or fatty acids include without limitation HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 40 stearate, polyoxyl 35 castor oil.
• ophthalmic compositions of the present disclosure include an aqueous, clear, mixed micellar solution.
• a formulation comprising a n ⁇ 40 polyoxyl lipid or fatty acid, and optionally, an active agent.
• the formulations includes nanomicelles.
• the polyoxyl lipid or fatty acid is a polyoxyl castor oil.
• the polyoxyl lipid or fatty acid is one or more selected from HCO-40, HCO-60, HCO-80 or HCO-100.
• the polyoxyl lipid or fatty acid (such as a polyoxyl castor oil such as HCO-40, HCO-60, HCO-80 or HCO-100) is present between 0.5 and 2%, or 0.7 and 2%, or 1 and 6%; or 2 and 6%; or 2 and 6%; or 3 and 6%; or 4 and 6%; or 2 and 5%; or 3 and 5%; or 3 and 5%; or 2 and 6%; or about 4%; or greater than 0.7%; or greater than 1%, or greater than 1.5%; or greater than 2%; or greater than 3%; or greater than 4% by weight of the formulation.
• the polyoxyl lipid is HCO-60.
• the polyoxyl lipid is HCO-80.
• the polyoxyl lipid is HCO-100.
• the formulation further includes polyalkoxylated alcohol.
• the formulation further includes polyalkoxylated alcohol that is octoxynol-40.
• the formulation includes a polyalkoxylated alcohol (such as octoxynol-40) present between 0.002 and 4%; or between 0.005 and 3%; or between 0.005 and 2%; or between 0.005 and 1%; or between 0.005 and 0.5%; or between 0.005 and 0.1%; or between 0.005 and 0.05%; or between 0.008 and 0.02%; or between 0.01 and 0.1%; or between 0.02 and 0.08%; or between 0.005 and 0.08%; or about 0.05%, or about 0.01% by weight of the formulation.
• a formulation that includes a polyoxyl lipid or fatty acid; and does not include an active agent, wherein said polyoxyl lipid or fatty acid is present in an amount equal to or greater than 1% of said formulation.
• a formulation that includes a polyoxyl lipid or fatty acid, and does not include an active agent; wherein said polyoxyl lipid or fatty acid is present in an amount equal to or greater than 0.05% of said formulation.
• the formulations includes nanomicelles.
• the polyoxyl lipid or fatty acid is a polyoxyl castor oil.
• the polyoxyl lipid or fatty acid is one or more selected from HCO-40, HCO-60, HCO-80 or HCO-100.
• the polyoxyl lipid or fatty acid (such as a polyoxyl castor oil such as HCO-60, HCO-80 or HCO-100) is present between 0.5 and 2%, or 0.7 and 2%, or between 1 and 6%; or 2 and 6%; or 2 and 6%; or 3 and 6%; or 4 and 6%; or 2 and 5%; or 3 and 5%; or 3 and 5%; or 2 and 6%; or about 4%; or greater than 1.5%; or greater than 2%; or greater than 3%; or greater than 4% by weight of the formulation.
• the polyoxyl lipid is HCO-40. In some embodiments the polyoxyl lipid is HCO-60. In some embodiments the polyoxyl lipid is HCO-80. In some embodiments the polyoxyl lipid is HCO-100. In some embodiments, the formulation further includes polyalkoxylated alcohol. In some embodiments, the formulation further includes polyalkoxylated alcohol that is octoxynol-40.
• the formulation includes a polyalkoxylated alcohol (such as octoxynol-40) present between 0.002 and 4%; or between 0.005 and 3%; or between 0.005 and 2%; or between 0.005 and 1%; or between 0.005 and 0.5%; or between 0.005 and 0.1%; or between 0.005 and 0.05%; or between 0.008 and 0.02%; or between 0.01 and 0.1%; or between 0.02 and 0.08%; or between 0.005 and 0.08%; or about 0.05%, or about 0.01% by weight of the formulation.
• a polyalkoxylated alcohol such as octoxynol-40
• a formulation that includes a polyoxyl lipid or fatty acid, and does not include an active agent; wherein said formulation comprises nanomicelles.
• the polyoxyl lipid or fatty acid is a polyoxyl castor oil.
• the polyoxyl lipid or fatty acid is one or more selected from HCO-40, HCO-60, HCO-80 or HCO-100.
• the polyoxyl lipid or fatty acid (such as a polyoxyl castor oil such as HCO-40, HCO-60, HCO-80 or HCO-100) is present between 0.5 and 2%, or 0.7 and 2%, or between 1 and 6%; or 2 and 6%; or 2 and 6%; or 3 and 6%; or 4 and 6%; or 2 and 5%; or 3 and 5%; or 3 and 5%; or 2 and 6%; or about 4%; or greater than 0.7%; or greater than 1%, or greater than 1.5%; or greater than 2%; or greater than 3%; or greater than 4% by weight of the formulation.
• the polyoxyl lipid is HCO-40.
• the polyoxyl lipid is HCO-60.
• the polyoxyl lipid is HCO-80. In some embodiments the polyoxyl lipid is HCO-100. In some embodiments, the formulation further includes polyalkoxylated alcohol. In some embodiments, the formulation further includes polyalkoxylated alcohol that is octoxynol-40.
• the formulation includes a polyalkoxylated alcohol (such as octoxynol-40) present between 0.002 and 4%; or between 0.005 and 3%; or between 0.005 and 2%; or between 0.005 and 1%; or between 0.005 and 0.5%; or between 0.005 and 0.1%; or between 0.005 and 0.05%; or between 0.008 and 0.02%; or between 0.01 and 0.1%; or between 0.02 and 0.08%; or between 0.005 and 0.08%; or about 0.05%, or about 0.01% by weight of the formulation.
• a polyalkoxylated alcohol such as octoxynol-40
• a formulation comprising 1-5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.01% octoxynol-40, and does not include an active agent.
• a formulation comprising 1-5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.01% octoxynol-40, and does not include an active agent.
• a formulation comprising 1-5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.01% octoxynol-40, and does not include an active agent.
• a formulation comprising 1-5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.01% octoxynol-40, and does not include an active agent.
• a formulation comprising about 4% of HCO-60, about 0.01% octoxynol-40, and does not include an active agent.
• a formulation comprising 0.7-1.5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.05% octoxynol-40, and does not include an active agent.
• a formulation comprising 0.7-1.5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.05% octoxynol-40, and does not include an active agent.
• a formulation comprising 0.7-1.5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.05% octoxynol-40, and does not include an active agent.
• a formulation comprising 0.7-1.5% of one or more polyoxyl lipid selected from the group consisting of HCO-40, HCO-60, HCO-80 and HCO-100; about 0.05% octoxynol-40, and does not include an active agent.
• a formulation comprising about 1% of HCO-60, about 0.05% octoxynol-40, and does not include an active agent.
• the formulation includes nanomicelles.
• the formulation includes a polyoxyl lipid or fatty acid.
• the polyoxyl lipid or fatty acid is a polyoxyl castor oil.
• the polyoxyl lipid or fatty acid is one or more selected from HCO-40, HCO-60, HCO-80 or HCO-100.
• the polyoxyl lipid or fatty acid (such as a polyoxyl castor oil such as HCO-60, HCO-80 or HCO-100) is present between 0.5 and 2%, or 0.7 and 2%, or 1 and 6%; or 2 and 6%; or 2 and 6%; or 3 and 6%; or 4 and 6%; or 2 and 5%; or 3 and 5%; or 3 and 5%; or 2 and 6%; or about 4%; or greater than 0.7%; or greater than 1%, or greater than 1.5%; or greater than 2%; or greater than 3%; or greater than 4% by weight of the formulation.
• the polyoxyl lipid is HCO-40.
• the polyoxyl lipid is HCO-60.
• the polyoxyl lipid is HCO-80.
• the polyoxyl lipid is HCO-100.
• the formulation includes a polyalkoxylated alcohol.
• the formulation includes a polyalkoxylated alcohol that is octoxynol-40.
• the formulation includes a polyalkoxylated alcohol (such as octoxynol-40) present between 0.002 and 4%; or between 0.005 and 3%; or between 0.005 and 2%; or between 0.005 and 1%; or between 0.005 and 0.5%; or between 0.005 and 0.1%; or between 0.005 and 0.05%; or between 0.008 and 0.02%; or between 0.01 and 0.1%; or between 0.02 and 0.08%; or between 0.005 and 0.08%; or about 0.05%, or about 0.01% by weight of the formulation.
• the formulations of the present disclosure are formulated in the absence of any pharmaceutically active agent, i.e., any non-lipid non-surfactant pharmaceutically active agent that has received regulatory approval for the treatment of an ocular condition.
• Exemplary active agents which are optionally excluded from the formulations of the present disclosure include one or more selected from the group consisting of calcineurin inhibitors, mTOR inhibitors, peptides, eicosanoids (e.g. prostacyclins and prostaglandins), anti-inflammatory drugs (such as NSAIDS), autonomic drugs (e.g. beta-blockers, alpha-blockers, beta-agonists, and alpha-agonists), biologics, gene therapy agents (e.g. viral vectors), anti-infectives (e.g.
• retinoids retinoids
• RNAi photo sensitizers
• steroids e.g., estrogens and derivatives thereof, and corticosteroids
• mixture drugs immuno-modulators, chemotherapeutic agents, G-coupled protein receptor antagonists, receptor tyrosine kinase (RTK) inhibitors, growth hormone inhibitors, integrin inhibitors, Sdf1/CXCR4 pathway inhibitors, and nACh receptor antagonists, resolvins (resolvin-like compounds), lipoxins, neuroprotectins, maresins and oxylipins.
• chemotherapeutic agents e.g., G-coupled protein receptor antagonists, receptor tyrosine kinase (RTK) inhibitors, growth hormone inhibitors, integrin inhibitors, Sdf1/CXCR4 pathway inhibitors, and nACh receptor antagonists, resolvins (resolvin-like compounds), lipoxins, neuroprotectins, maresins and oxylipin
• the active ingredients which are optionally excluded from the formulations of the present disclosure include one or more selected from the group consisting of cyclosporine A, voclosporin, ascomycin, tacrolimus, pimecrolimus, an analog thereof, or a pharmaceutically acceptable salt thereof.
• the active agent is cyclosporine A.
• the active agent is voclosporin.
• the active ingredients which are optionally excluded from the formulations of the present disclosure include one or more selected from the group consisting of sirolimus (rapamycin), temsirolimus, everolimus, an analog thereof, or a pharmaceutically acceptable salt thereof.
• the active agents which are optionally excluded from the formulations of the present disclosure include a resolvin or a resolvin-like compound.
• a resolvin-like compound includes resolvins and compounds with similar structures and/or features.
• Resolvins and resolvin-like compounds include a compound of formula A, a compound of any one of formulae 1-49, a compound of any one of formulae I-IX, a lipoxin compound, an oxylipin compound, a prodrug of any of the foregoing, or a pharmaceutically acceptable salt of any of the foregoing.
• the active agent which is optionally excluded from the formulations of the present disclosure includes compounds selected from a compound of any one of Formulae 1 to 115.
• the active agent which is optionally excluded from the formulations of the present disclosure includes a compound of formula I,
• the stereochemistry of the carbon qq′ to carbon rr′ double bond is cis or trans
• the stereochemistry of the carbon ss' to carbon tt′ double bond is cis or trans
• Re, Rf, R 5 , and E are as defined above.
• a compound of formula I or II is which is optionally excluded from the formulations of the present disclosure is represented by formula III,
• the active agent which is optionally excluded from the formulations of the present disclosure is a compound of formula I, wherein: Re, Rf, Rh, Ri, R 8 and R 9 are hydrogen; E is branched alkoxy (such as isopropyl); and R 5 is CH 2 CH 2 CH 2 .
• the active agent which is optionally excluded from the formulations of the present disclosure is a compound 1001 or a pharmaceutically acceptable salt thereof.
• acyl is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)—, preferably alkylC(O)—.
• acylamino is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH—.
• acyloxy is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O—, preferably alkylC(O)O—.
• alkoxy refers to an alkyl group, preferably a lower alkyl group, having an oxygen attached thereto.
• Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
• alkoxyalkyl refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.
• alkenyl refers to an aliphatic group containing at least one double bond and is intended to include both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the alkenyl group. Such substituents may occur on one or more carbons that are included or not included in one or more double bonds. Moreover, such substituents include all those contemplated for alkyl groups, as discussed below, except where stability is prohibitive. For example, substitution of alkenyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.
• alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
• a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chains, C 3 -C 30 for branched chains), and more preferably 20 or fewer.
• preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
• alkyl (or “lower alkyl”) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
• Such substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety.
• a halogen
• the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
• the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF 3 , —CN and the like.
• Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF 3 , —CN, and the like.
• C x-y when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain.
• C x-y alkyl refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-tirfluoroethyl, etc.
• C 0 alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
• C 2-y alkenyl and C 2-y alkynyl refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
• alkylamino refers to an amino group substituted with at least one alkyl group.
• alkylthio refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS—.
• alkynyl refers to an aliphatic group containing at least one triple bond and is intended to include both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the alkynyl group. Such substituents may occur on one or more carbons that are included or not included in one or more triple bonds. Moreover, such substituents include all those contemplated for alkyl groups, as discussed above, except where stability is prohibitive. For example, substitution of alkynyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.
• amide refers to a group
• each R 10 independently represent a hydrogen or hydrocarbyl group, or two R 10 are taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
• amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
• each R 10 independently represents a hydrogen or a hydrocarbyl group, or two R 10 are taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
• aminoalkyl refers to an alkyl group substituted with an amino group.
• aralkyl refers to an alkyl group substituted with an aryl group.
• aryl as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
• the ring is a 5- to 7-membered ring, more preferably a 6-membered ring.
• aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
• Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
• R 9 and R 10 independently represent hydrogen or a hydrocarbyl group, such as an alkyl group, or R 9 and R 10 taken together with the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring structure.
• carbocycle refers to a non-aromatic saturated or unsaturated ring in which each atom of the ring is carbon.
• a carbocycle ring contains from 3 to 10 atoms, more preferably from 5 to 7 atoms.
• Carbocyclylalkyl refers to an alkyl group substituted with a carbocycle group.
• carbonate is art-recognized and refers to a group —OCO 2 —R 10 , wherein R 10 represents a hydrocarbyl group.
• esters refers to a group —C(O)OR 10 wherein R 10 represents a hydrocarbyl group.
• ether refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O—. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.
• halo and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
• heteroalkyl and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.
• heteroalkyl refers to a saturated or unsaturated chain of carbon atoms and at least one heteroatom, wherein no two heteroatoms are adjacent.
• heteroaryl and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
• heteroaryl and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
• Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
• heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
• heterocyclyl refers to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
• heterocyclyl and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
• Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
• heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
• hydrocarbyl refers to a group that is bonded through a carbon atom that does not have a ⁇ O or ⁇ S substituent, and typically has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms.
• groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a ⁇ O substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not.
• Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
• hydroxyalkyl refers to an alkyl group substituted with a hydroxy group.
• lower when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer non-hydrogen atoms in the substituent, preferably six or fewer.
• acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).
• polycyclyl refers to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”.
• Each of the rings of the polycycle can be substituted or unsubstituted.
• each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
• sil refers to a silicon moiety with three hydrocarbyl moieties attached thereto.
• substituted refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
• the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
• the permissible substituents can be one or more and the same or different for appropriate organic compounds.
• the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
• Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic mo
• sulfate is art-recognized and refers to the group —OSO 3 H, or a pharmaceutically acceptable salt thereof.
• R 9 and R 10 independently represents hydrogen or hydrocarbyl, such as alkyl, or R 9 and R 10 taken together with the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring structure.
• sulfoxide is art-recognized and refers to the group —S(O)—R 10 , wherein R 10 represents a hydrocarbyl.
• sulfonate is art-recognized and refers to the group SO 3 H, or a pharmaceutically acceptable salt thereof.
• sulfone is art-recognized and refers to the group —S(O) 2 —R 10 , wherein R 10 represents a hydrocarbyl.
• thioalkyl refers to an alkyl group substituted with a thiol group.
• thioester refers to a group —C(O)SR 10 or —SC(O)R 10 wherein R 10 represents a hydrocarbyl.
• thioether is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
• urea is art-recognized and may be represented by the general formula
• R 9 and R 10 independently represent hydrogen or a hydrocarbyl, such as alkyl, or either occurrence of R 9 taken together with R 10 and the intervening atom(s) complete a heterocycle having from 4 to 8 atoms in the ring structure.
• Protecting group refers to a group of atoms that, when attached to a reactive functional group in a molecule, mask, reduce or prevent the reactivity of the functional group. Typically, a protecting group may be selectively removed as desired during the course of a synthesis. Examples of protecting groups can be found in Greene and Wuts, Protective Groups in Organic Chemistry, 3 rd Ed., 1999, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods , Vols. 1-8, 1971-1996, John Wiley & Sons, NY.
• nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilyl-ethanesulfonyl (“TES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitro-veratryloxycarbonyl (“NVOC”) and the like.
• hydroxylprotecting groups include, but are not limited to, those where the hydroxyl group is either acylated (esterified) or alkylated such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS or TIPS groups), glycol ethers, such as ethylene glycol and propylene glycol derivatives and allyl ethers.
• the present disclosure further relates to treating or preventing ocular diseases or disorders, for example by local administration of the formulations as described herein.
• a patient or subject to be treated by any of the compositions or methods of the present disclosure can mean either a human or a non-human animal.
• the present disclosure provides methods for the treatment of an ocular disease in a human patient in need thereof.
• the present disclosure provides methods for the treatment of an inflammatory ocular disease in a human patient in need thereof.
• the present disclosure provides methods for the treatment of an ocular disease in a veterinary patient in need thereof, including, but not limited to dogs, horses, cats, rabbits, gerbils, hamsters, rodents, birds, aquatic mammals, cattle, pigs, camelids, and other zoological animals.
• the active agent when present, may include a combination of two or more different active ingredients.
• the active agent when present, may include two or more active agents selected from the group consisting of a resolvin or resolvin-like compound, a steroid (such as a corticosteroid), cyclosporine A, and voclosporin.
• the active agent when present, may include a resolvin and cyclosporine A.
• the active agent, when present may include a resolvin and a corticosteroid.
• the active agent when present, may include cyclosporine A and a corticosteroid.
• the active agent when present, may include a resolvin, cyclosporine A and a corticosteroid.
• the active agent when present, may include two or more active agents and one of said active agents is an antibiotic, for example one or more antibiotics selected from the group consisting of azythromycin, ciprofloxacin, ofloxacin, gatifloxacin, levofloxacin, moxifloxacin, besifloxacin, and levofloxacin.
• the active agent when present, may include two or more active agents and one of the active agents is an antibiotic, for example one or more antibiotics selected from the group consisting of azythromycin, ciprofloxacin, ofloxacin, gatifloxacin, levofloxacin, moxifloxacin, besifloxacin, and levofloxacin; and a second of such agents is a resolvin such as described herein (including without limitation compound 1001).
• an antibiotic for example one or more antibiotics selected from the group consisting of azythromycin, ciprofloxacin, ofloxacin, gatifloxacin, levofloxacin, moxifloxacin, besifloxacin, and levofloxacin
• a second of such agents is a resolvin such as described herein (including without limitation compound 1001).
• the active agent when present, may include two or more active agents and one of said active agents is an antiviral, for example one or more antivirals selected from the group consisting of ganciclovir, trifluridine, acyclovir, famciclovir, valacyclovir, penciclovir and cidofovir.
• an antiviral for example one or more antivirals selected from the group consisting of ganciclovir, trifluridine, acyclovir, famciclovir, valacyclovir, penciclovir and cidofovir.
• the active agent when present, may include two or more active agents and one of the active agents is an antibiotic, for example one or more antivirals selected from the group consisting of ganciclovir, trifluridine, acyclovir, famciclovir, valacyclovir, penciclovir and cidofovir; and a second of the active agents is a resolvin such as described herein (including without limitation compound 1001).
• one of the active agents is an antibiotic, for example one or more antivirals selected from the group consisting of ganciclovir, trifluridine, acyclovir, famciclovir, valacyclovir, penciclovir and cidofovir; and a second of the active agents is a resolvin such as described herein (including without limitation compound 1001).
• treating refers to: preventing a disease, disorder or condition from occurring in a cell, a tissue, a system, animal or human which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; stabilizing a disease, disorder or condition, i.e., arresting its development; and/or relieving one or more symptoms of the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.
• a therapeutic that “prevents” a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
• ocular disease As used herein, the terms “ocular disease,” “ocular condition,” “eye disease,” and “eye condition” refer to diseases/conditions of the eye(s) that can be sight threatening, lead to eye discomfort, and may signal systemic health problems.
• anterior segment disease refers to all disorders that affect the eye surface, anterior chamber, iris and ciliary body and lens of the eye.
• the eye surface is composed of the cornea, conjunctiva, eyelids, lacrimal and meibomian glands, and the interconnecting nerves.
• posterior segment eye disease and “back-of-the-eye disease” refer to all disorders that affect the posterior segment of the eye.
• a posterior eye disease is a disease which primarily affects a posterior ocular site such as choroid or sclera, vitreous, vitreous chamber, retina, optic nerve, and blood vessels and nerves which vascularize or innervate a posterior ocular site.
• a method treating or preventing an ocular disease or condition that includes locally administering a formulation of any of the aspects or embodiments as disclosed herein.
• the ocular disease is an anterior segment disease.
• the ocular disease is a posterior segment disease.
• the ocular disease is one or more selected from the group consisting of dry eye syndrome, Sjogren's syndrome, uveitis, anterior uveitis (iritis), chorioretinitis, posterior uveitis, conjunctivitis, allergic conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis, systemic immune mediated diseases such as cicatrizing conjunctivitis and other autoimmune disorders of the ocular surface, blepharitis, scleritis, age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), ocular neovascularization, age-related macular degeneration (ARMD), proliferative vitreoretinopathy (PVR), cytomegalovirus (CMV) retinitis, optic
• the ocular disease is dry eye. In one embodiment, the ocular disease is allergic conjunctivitis. In one embodiment the ocular disease is age-related macular degeneration (AMD). In one embodiment the ocular disease is diabetic retinopathy.
• a formulation of any of the aspects or embodiments disclosed herein are used as artificial tears; for example the formulations may be used to moisten and lubricate eyes. The formulations provided herein may also, or alternatively, be used to moisten contact lenses or to moisten eyes in the presence of contact lenses. In certain embodiments the formulations provided herein may be “over-the-counter”; ie offered directly to a consumer without the need for a prescription from a health care provider.
• the formulations of the present disclosure are formulated in the absence of any pharmaceutically active agent, i.e., any non-lipid non-surfactant pharmaceutically active agent that has received regulatory approval for the treatment of an ocular condition.
• active agents that may be specifically excluded from various embodiments of the formulations herein may be any agent capable of affecting a biological process, especially agents that have received regulatory approval for the treatment of an ocular condition.
• Active agents (the term active ingredient is used herein interchangably with the term active agent) contemplated for exclusion herein may include drugs, hormones, cytokines, toxins, therapeutic agents, vitamins, and the like.
• active agents contemplated for exclusion herein in accordance with the aspects and embodiments disclosed herein are agents capable of, or approved for, treating or preventing a disease or condition, for example in some embodiments an active agent is capable of, or approved for, treating or preventing an ocular disease or condition.
• compositions of the present disclosure can be used as a topically applied or locally injected drug delivery platform for delivery of a variety of active agents including hydrophobic, water-insoluble drugs.
• Active agents for which delivery may be enhanced by compositions of the present disclosure, but which may be excluded from compositions of the present disclosure may include calcineurin inhibitors or mTOR inhibitors, peptides, eicosanoids (e.g. prostacyclins and prostaglandins), anti-inflammatory drugs, autonomic drugs (e.g. beta-blockers, alpha-blockers, beta-agonists, and alpha-agonists), biologics, gene therapy agents (e.g. viral vectors), anti-infectives (e.g.
• retinoids retinoids
• RNAi photo sensitizers
• steroids e.g., estrogens and derivatives thereof
• mixture drugs immuno-modulators, chemotherapeutic agents, G-coupled protein receptor antagonists, receptor tyrosine kinase (RTK) inhibitors, growth hormone inhibitors, integrin inhibitors, Sdf1/CXCR4 pathway inhibitors, and nACh receptor antagonists, resolvins, lipoxins, oxylipins and the like.
• RTK receptor tyrosine kinase
• the active agent for which delivery may be enhanced by compositions of the present disclosure, but which may be excluded from compositions of the present disclosure is a corticosteroid, including prednisolone, hydrocortisone, triamcinolone and budesonide.
• the active ingredient for which delivery may be enhanced by compositions of the present disclosure, but which may be excluded from compositions of the present disclosure may be a non-steroidal anti-inflammatory drug (NSAID), for example Cox-2 inhibitors such as celecoxib, ruboxistaurin and nimesulide.
• NSAID non-steroidal anti-inflammatory drug
• an active agent for which delivery may be enhanced by compositions of the present disclosure may be an anti-growth factor molecule including, but are not limited to, vascular endothelial growth factor (VEGF) inhibitors such as, pegaptanib (macugen), ranibizumab (lucentis), and bevacizumab (avastin).
• VEGF vascular endothelial growth factor
• the active agent for which delivery may be enhanced by compositions of the present disclosure is an antibiotic, for example one or more antibiotics selected from the group consisting of azythromycin, ciprofloxacin, ofloxacin, gatifloxacin, levofloxacin, moxifloxacin, besifloxacin, and levofloxacin.
• the active agent for which delivery may be enhanced by compositions of the present disclosure is an antiviral, for example one or more antivirals selected from the group consisting of ganciclovir, trifluridine, acyclovir, famciclovir, valacyclovir, penciclovir and cidofovir.
• compositions of the present disclosure include an active agent
• an active agent a combination of two active agents may be used, including but not limited to a vascular endothelial growth factor (VEGF) inhibitor and an antagonist of platelet-derived growth factor (PDGF).
• VEGF vascular endothelial growth factor
• PDGF platelet-derived growth factor
• compositions of the present disclosure when compositions of the present disclosure include an active agent, the following active agents may be excluded from compositions of the present disclosure: calcineurin inhibitors such as cyclosporine A, voclosporin, ascomycin, tacrolimus, pimecrolimus, an analog thereof, or a pharmaceutically acceptable salt thereof.
• active agents such as cyclosporine A, voclosporin, ascomycin, tacrolimus, pimecrolimus, an analog thereof, or a pharmaceutically acceptable salt thereof.
• compositions of the present disclosure when compositions of the present disclosure include an active agent, the following active agents may be excluded from compositions of the present disclosure: a mTOR inhibitor such as sirolimus (rapamycin), temsirolimus, everolimus, an analog thereof, or a pharmaceutically acceptable salt thereof.
• a mTOR inhibitor such as sirolimus (rapamycin), temsirolimus, everolimus, an analog thereof, or a pharmaceutically acceptable salt thereof.
• compositions of the present disclosure when compositions of the present disclosure include an active agent, resolvins are excluded as the active agent.
• compounds of formula A are excluded as the active agent
• compounds of any one of formulae 1-49 are excluded as the active agent
• compounds of any one of formulae I-IX are excluded as the active agent
• lipoxin compounds are excluded as the active agent
• oxylipin compounds are excluded as the active agent
• prodrug of any of the foregoing or a pharmaceutically acceptable salt of any of the foregoing are excluded as the active agent.
• compositions of the present disclosure include those of Formula A,
• Y′ is connected to V 1 via a carbon atom
• n′ is 0 or 1; otherwise n′ is 1;
• L′ is additionally selected from W′; and n′ is 0 or 1;
• R 1003 are R b′ both hydrogen
• Q′ represents one or more substituents and each Q′ is independently selected from halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, amino, hydroxy, cyano, carboxyl, alkoxycarbonyloxy, aryloxycarbonyloxy or aminocarbonyl.
• V 1 is selected from
• V 2 is selected from a bond
• n′ when q′ is 0 and V 3 is a bond, n′ is 0 or 1; otherwise n′ is 1.
• p′ is 0, 1, 2, 3, or 5.
• q′ is 0 or 1.
• o′ is 0 or 1
• p′ is 1 or 2
• o′+p′ is 1 or 2
• V 2 is
• V 3 is a bond.
• o′ is 3, 4 or 5
• p′ is 0, 1 or 2
• o′+p′ is 4 or 5
• V 2 is a bond.
• V 2 is a bond
• o′ is 0, 3, 4 or 5
• p′ is 0, 1, 2 or 5
• o′+p′ is 4 or 5
• q′ is 0, and V 3 is a bond.
• each of W′ and Y′ is independently selected from a bond or lower alkyl or heteroalkyl optionally substituted with one or more substituents independently selected from alkenyl, alkynyl, aryl, chloro, iodo, bromo, fluoro, hydroxy, amino, or oxo.
• the compound of formula A is other than a compound of formulae 48, 48a, 48b, 48c, or 48d.
• V 1 is
• V 2 is
• q′ is 1, and V 3 is a bond, at least one occurrence of R 1001 is other than hydrogen.
• a pharmaceutically acceptable salt of the compound is formed by derivatizing E, wherein E is —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn.
• compositions of the present disclosure include an active agent
• a compound of formula 1, represented by formula 2 is optionally excluded from such compositions:
• compositions of the present disclosure include an active agent
• a pharmaceutically acceptable salt of the compound formed by derivatizing E wherein E is —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn is optionally excluded from such compositions.
• Exemplary compounds of formula 2 optionally excluded from such compositions include compound 2a,
• compositions of the present disclosure include an active agent, a compound of formula 1, represented by formula 3, is optionally excluded from such compositions
• compositions of the present disclosure include an active agent
• a pharmaceutically acceptable salt of the compound formed by derivatizing E wherein E is —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn is optionally excluded from such compositions.
• Exemplary compounds of formula 3 optionally excluded from such compositions include compound 3a,
• compositions include Compound X,
• compositions of the present disclosure include an active agent, include those of Formula 4,
• Exemplary compounds of formula 4 optionally excluded from such compositions include compound 4a,
• compositions of the present disclosure include an active agent, include those of Formula 5,
• the stereochemistry of the carbon ii′ to carbon jj′ bond is trans.
• Exemplary compounds of formula 5 optionally excluded from such compositions include compound 5a,
• compositions of the present disclosure include an active agent, include those of Formula 6,
• the stereochemistry of the carbon gg′ to carbon hh′ bond is trans.
• Exemplary compounds of formula 6 is optionally excluded from such compositions include compound 6a,
• compositions of the present disclosure include an active agent, include those of Formula 7,
• carbons e′ and f′ are connected by a cis double bond.
• carbons g′ and h′ are connected by a double bond.
• carbons e′ and f′ are connected by a cis double bond and carbons g′ and h′ are connected by a double bond.
• Exemplary compounds of formula 7 optionally excluded from such compositions include compound 7a,
• compositions of the present disclosure include an active agent, include those of Formula 8,
• the stereochemistry of the carbon i′ to carbon j′ bond is cis.
• Exemplary compounds of formula 8 optionally excluded from such compositions include compound 8a,
• compositions of the present disclosure include an active agent, include those of Formula 9,
• the stereochemistry of the carbon m′ to carbon n′ double bond is cis.
• carbons k′ and l′ are connected by a cis double bond.
• the stereochemistry of the carbon m′ to carbon n′ double bond is cis and carbons k′ and l′ are connected by a cis double bond.
• Exemplary compounds of formula 9 optionally excluded from such compositions include compound 9a,
• compositions of the present disclosure include those of Formula 10,
• compositions of the present disclosure include an active agent, include those of Formula 11,
• P 1 , P 2 , P 3 , R 1 , and Z are as defined above.
• compositions of the present disclosure include an active agent, include those of Formula 12,
• compositions of the present disclosure include an active agent, include those of Formula 13,
• P 1 , P 2 , R 1 , R 2 , U, and Z are as defined above.
• compositions of the present disclosure include an active agent, include those of Formula 14,
• P 1 , P 2 , R 1 , R 2 , Q, and Z are as defined above.
• compositions of the present disclosure include an active agent, include those of Formula 15,
• P 1 , P 2 , and Z are as defined above.
• compositions of the present disclosure include an active agent, include those of Formula 16,
• compositions of the present disclosure include an active agent, include those of Formula 17,
• compositions of the present disclosure include an active agent, include those of Formula 18,
• the stereochemistry of the carbon s′ to carbon t′ double bond is cis or trans
• the stereochemistry of the carbon u′ to carbon v′ double bond is cis or trans
• P 1 , P 2 , R 1 , R 2 , and Z are as defined above.
• compositions of the present disclosure include an active agent, include those of Formula 19,
• Carbons w′ and x′ are connected by a single or a double bond; Carbons y′ and z′ are connected by a single or a double bond; and P 1 , P 2 , and Z are as defined above.
• each R b is a suitable group independently selected from ⁇ O, —OR d , (C1-C3) haloalkyloxy, —OCF 3 , ⁇ S, —SR d , ⁇ NR d , ⁇ NOR d , —NR c R c , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ⁇ N 2 , —N 3 , —S(O)R d , —S(O) 2 R d , —S(O) 2 OR d , —S(O)NR c R c , —S(O) 2 NR c R c , —OS(O)R d , —OS(O) 2 R d , —OS(O) 2 OR d , —OS(O) 2 NR
• compositions of the present disclosure include those of Formula 20,
• each P is individually selected from H or a protecting group; and R is H, C 1-6 alkyl (e.g., methyl, ethyl, glycerol), C 2-6 alkenyl or C 2-6 alkynyl.
• Exemplary compounds of formula 21 is optionally excluded from such compositions include compound 21a,
• compositions of the present disclosure include those of Formula 29,
• a compound of Formula 29, as represented by Formula 30, is optionally excluded from such compositions,
• D 1 -E 1 and F 1 -G 1 are independently are cis or trans —C ⁇ C— or —C ⁇ C—; and R 101 , R 102 , R 103 , R 104 , W 1 , R 105 , A 1 , X 1 , n, Y 1 , R 100 , R a1 , and R c1 are as defined above.
• compositions of the present disclosure include an active agent, include those of Formulae 31 to 37
• R 106 is —OH, —OCH 3 , —OCH(CH 3 ) 2 or —NHCH 2 CH 3 ;
• compositions of the present disclosure include an active agent, include those of Formula 38,
• R 8 and R 9 are hydrogen.
• a pharmaceutically acceptable salt of the compound formed by derivatizing E, wherein E is —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn is optionally excluded from such compositions.
• compositions of the present disclosure include an active agent, include those of Formulae 39-44,
• Exemplary compounds of formulae 39, 41, and 43 include:
• compositions of the present disclosure include an active agent
• a pharmaceutically acceptable salt of the compound formed by derivatizing E wherein E is —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn is optionally excluded from such compositions.
• E is —OM
• M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn
• examples of such compounds include compound Z,
• compositions of the present disclosure include an active agent, include those of Formula 46,
• compositions of the present disclosure include an active agent, include those of Formula 47,
• a compound of formula 47 is represented by formula 48,
• the stereochemistry of the carbon kk′ to carbon ll′ double bond is cis or trans; the stereochemistry of the carbon mm′ to carbon nn′ double bond is cis or trans; the stereochemistry of the carbon oo′ to carbon pp′ double bond is cis or trans.
• the stereochemistry of the carbon kk′ to carbon ll′ double bond is trans.
• the stereochemistry of the carbon mm′ to carbon nn′ double bond trans is the stereochemistry of the carbon mm′ to carbon nn′ double bond trans.
• the stereochemistry of the carbon oo′ to carbon pp′ double bond is cis.
• the stereochemistry of the carbon kk′ to carbon ll′ double bond is trans
• the stereochemistry of the carbon mm′ to carbon nn′ double bond trans is trans
• the stereochemistry of the carbon oo′ to carbon pp′ double bond is cis
• a compound of formula 47 is represented by compound 48a,
• a compound of formula 47 is represented by formula 48d,
• the stereochemistry of the carbon kk′ to carbon ll′ double bond is cis or trans; the stereochemistry of the carbon mm′ to carbon nn′ double bond is cis or trans; the stereochemistry of the carbon oo′ to carbon pp′ double bond is cis or trans.
• the compound of formula 47 is other than a compound of formula 48, 48a, 48b, 48c, or 48d.
• compositions of the present disclosure include an active agent, include those of Formula 49,
• Exemplary compounds of formula 49 include compound 49a,
• the compounds above are known to be useful in the treatment or prevention of inflammation or inflammatory disease.
• Examples of such compounds are disclosed in the following patents and applications: US 2003/0191184, WO 2004/014835, WO 2004/078143, U.S. Pat. No. 6,670,396, US 2003/0236423, US 2005/0228047, US 2005/0238589 and US2005/0261255. These compounds are optionally excluded for use in methods of the present disclosure.
• compositions of the present disclosure are compounds that are chemically similar variants to any of the compounds of formula A or formulae 1-49 set forth above.
• chemically similar variants includes, but is not limited to, replacement of various moieties with known biosteres; replacement of the end groups of one of the compounds above with a corresponding end group of any other compound above, modification of the orientation of any double bond in a compound, the replacement of any double bond with a triple bond in any compound, and the replacement of one or more substituents present in one of the compounds above with a corresponding substituent of any other compound.
• Lipoxin compounds optionally excluded for use as active agents, when compositions of the present disclosure include an active agent, include those of formula 50:
• Z i , Z ii , Z iii , Z iv and Z v are each independently selected from —NO 2 , —CN, —C( ⁇ O)—R 301 , —SO 3 H, a hydrogen atom, halogen, methyl, —OR x , wherein R x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl, wherein when any of Z i , Z ii , Z iii , Z iv or Z v is C( ⁇ O)—R 301 , said Z i , Z ii , Z iii , Z iv or Z v is not substituted with another C( ⁇ O)—R 301 .
• Z i , Z ii , Z iii , Z iv and Z v are defined as above;
• Lipoxin compounds optionally excluded for use as active agents in such compositions, when compositions of the present disclosure include an active agent, include those of formulae 51, 52, 53 or 54:
• Lipoxin compounds optionally excluded for use as active agents in such compositions, when compositions of the present disclosure include an active agent, include those of formula 55:
• R 401 is selected from:
• R 402 is selected from:
• X 10 is R 411 , OR 411 , or SR 411 ;
• Z i , Z ii , Z iii , Z iv and Z v are each independently selected from —NO 2 , —CN, —C( ⁇ O)—R 411 , —SO 3 H, a hydrogen atom, halogen, methyl, —OR x , wherein R x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; wherein when any of Z i , Z ii , Z iii , Z iv or Z v is C( ⁇ O)—R 411 , said Z i , Z ii , Z iii , Z iv or Z v is not substituted with another C( ⁇ O)—R 411 .
• Q 3 is O, S or NH
• R 412 and R 413 are a hydrogen atom and the other is selected from:
• Lipoxin compounds optionally excluded for use as active agents in such compositions, when compositions of the present disclosure include an active agent, include those of formula 56:
• E is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, and the cations of sodium, potassium, magnesium and zinc;
• W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide;
• each of R 501 -R 503 are independently selected from hydrogen, alkyl, aryl, acyl or alkoxyacyl;
• n 0, 1 or 2;
• n 1 or 2;
• the two substituents on the phenyl ring are ortho, meta, or para.
• Lipoxin compounds optionally excluded for use as active agents in such compositions, when compositions of the present disclosure include an active agent, include those of formula 57:
• I is selected from: —C(O)-E, —SO 2 -E, —PO(OR)-E, where E is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino, or —OM, where M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn; and R is hydroxyl or alkoxy
• J′ and K′ are linkers independently selected from a chain of up to 20 atoms and a ring containing up to 20 atoms, provided that J′ and K′ can independently include one or more nitrogen, oxygen, sulfur or phosphorous atoms, and further provided that J′ and K′ can independently include one or more substituents selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, chloro, iodo, bromo, fluoro, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, cyano, oxo, thio, alkylthio, arylthio, acylthio, alkylsulfonate, arylsulfonate, phosphoryl, and sulfonyl, and further provided that J′ and K′ can also contain one or more fused carbocyclic, heterocyclic, ary
• G is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, chloro, iodo, bromo, fluoro, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, and carboxamido.
• Re, Rf and Rg are independently selected from hydrogen, alkyl, aryl, heteroaryl, acyl, silyl, alkoxyacyl and aminoacyl;
• R 601 , R 602 and R 603 are independently selected from hydrogen, alkyl, aryl and heteroaryl, provided that R 601 , R 602 and R 603 can independently be connected to linkers J′ or K′;
• R 604 and R 605 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, fluoro, and provided that R 604 and R 605 can be joined together to form a carbocyclic, heterocyclic or aromatic ring, and further provided that R 604 and R 605 can be replaced by a bond to form a triple bond.
• compositions of the present disclosure include an active agent
• examples of such compounds are those of formulae 58-115, as shown in Table 1. These compounds include long chain omega-6 fatty acids, docosapentaenoic acid (DPAn-6) (compounds 58-73) and docosatetraenoic acid (DTAn-6) (compounds 74-83), and the omega-3 counterpart of DPAn-6, docosapentaenoic acid (DPAn-3) (compounds 84-97). Further compounds are the docosanoids 98-115, the ⁇ -linolenic acids (GLA) (compounds 116-122), and the stearidonic acids (SDA) (compounds 123-132).
• GLA ⁇ -linolenic acids
• SDA stearidonic acids
• compositions of the present disclosure include an active agent
• Such compounds include but are not limited to those analogs wherein one or more double bonds are replaced by triple bonds, those wherein one or more carboxy groups are derivatized to form esters, amides or salts, those wherein the hydroxyl-bearing carbons are further derivatized (with, for example, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, or alkynyl group, substituted or unsubstituted aryl group, substituted or unsubstituted, branched or unbranched alkylaryl group, halogen atom) to form tertiary alcohols (or ethers, esters, or other derivatives thereof), those wherein one or more hydroxyl groups are derivatized to form esters or protected alcohols, or those having combinations of any of the fore
• compositions of the present disclosure include an active agent, include the following: isolated docosanoids of docosapentaenoic acid (DPAn-6); monohydroxy, dihydroxy, and trihydroxy derivatives of DPAn-6; isolated docosanoids of docosapentaenoic acid (DPAn-3); monohydroxy, dihydroxy, and trihydroxy derivatives of DPAn-3; isolated docosanoids of docosapentaenoic acid (DTAn-6); or monohydroxy, dihydroxy, and trihydroxy derivatives of DTAn-6.
• DPAn-6 isolated docosanoids of docosapentaenoic acid
• DPAn-6 isolated docosanoids of docosapentaenoic acid
• DPAn-6 isolated docosanoids of docosapentaenoic acid
• DPAn-6 isolated docosanoids of docosapentaenoic acid
• DPAn-6 isolated docosanoids of docosapent
• compositions of the present disclosure include an active agent, include compounds of formula I,
• an active agent optionally excluded from such compositions when compositions of the present disclosure include an active agent, may be a compound of formula Ia,
• a compound of formula I is represented by formula II,
• the stereochemistry of the carbon qq′ to carbon rr′ double bond is cis or trans
• the stereochemistry of the carbon ss' to carbon tt′ double bond is cis or trans
• Re, Rf, R 5 , and E are as defined above.
• an active agent optionally excluded from such compositions when compositions of the present disclosure include an active agent, may be a compound of formula IIa,
• a compound of formula I or II is represented by formula III,
• R represents an alkyl group, preferably a lower alkyl group, that is branched at the position bonded to the oxygen atom is optionally excluded from such compositions.
• R moieties include —CH(CH 3 ) 2 (isopropyl), —CH(CH 2 CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ) (sec-butyl), and —C(CH 3 ) 3 (tert-butyl).
• Exemplary compounds of formulae I, II, and III include compound 1001
• an active agent optionally excluded from such compositions when compositions of the present disclosure include an active agent, may be a compound of formula IV,
• R 1 is —OM
• M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn, is optionally excluded from such compositions.
• R 2 and R 1 together are
• X is —C ⁇ C—. In certain embodiments, X is —C(R 7 ) ⁇ C(R 7 )—, -(cyclopropyl)-, -(cyclobutyl)-, -(cyclopentyl)-, or -(cyclohexyl)-. In certain embodiments, X is —C(R 7 ) ⁇ C(R 7 )—. In certain embodiments, X is -(cyclopropyl)-, -(cyclobutyl)-, -(cyclopentyl)-, or -(cyclohexyl)-. In certain embodiments, X is -(cyclopropyl)-.
• X is —C ⁇ C— or —C(R 7 ) ⁇ C(R 7 )—.
• X is -(cyclopropyl)-, -(cyclobutyl)-, -(cyclopentyl)-, or -(cyclohexyl)-
• the olefin and the carbon bearing R 4a are attached to adjacent carbons on the -(cyclopropyl)-, -(cyclobutyl)-, -(cyclopentyl)-, or -(cyclohexyl)- ring system.
• R 4b is hydrogen. In certain embodiments, R 4b is halo, —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, or —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxy
• R 4b is fluoro.
• R 4b is hydrogen, —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, or —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxy
• Rob is selected from —OH, —O—(C 1 -C 5 )-alkyl, O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, O—C(O)-aryl, O—C(O)-heteroaryl, and —O—C(O)—N(R a )(R b ).
• R 4b is hydrogen, halo, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, or —O—C(O)—O-heteroaryl, wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxyl, carboxyl, ester, alkoxycarbonyl, acyl, thioester, thioacyl, thioether, amino, amido, acylamino, cyano, and nitro.
• R 4b is selected from hydrogen, halo, —OH, or —O—(C 1 -C 5 )-alkyl.
• R 4b is —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, or —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl
• R 4b is selected from —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, and —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxyl, carboxyl, ester, alkoxycarbon
• R 4b is in an (R) configuration. In certain embodiments, R 4b is in an (S) configuration.
• R 4a is hydrogen. In certain embodiments, R 4a is halo, —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, or —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxy
• R 4a is fluoro.
• R 4a is hydrogen, —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, or —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxy
• R 4a is selected from —OH, —O—(C 1 -C 5 )-alkyl, O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, O—C(O)-aryl, O—C(O)-heteroaryl, and —O—C(O)—N(R a )(R b ).
• R 4a is hydrogen, halo, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, or —O—C(O)—O-heteroaryl, wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxyl, carboxyl, ester, alkoxycarbonyl, acyl, thioester, thioacyl, thioether, amino, amido, acylamino, cyano, and nitro.
• R 4a is selected from hydrogen, halo, —OH, or —O—(C 1 -C 5 )-alkyl.
• R 4a is —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, or —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl
• R 4a is selected from —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, and —O—C(O)—N(R a )(R b ), wherein any alkyl, aryl or heteroaryl is optionally substituted with up to 3 substituents independently selected from halo, (C 1 -C 5 )-alkyl, O—(C 1 -C 5 )-alkyl, hydroxyl, carboxyl, ester, alkoxycarbon
• R 4a is in an (S) configuration. In certain embodiments, R 4a is in an (R) configuration.
• R 5a is selected from hydrogen or (C 1 -C 5 )-alkyl. In certain embodiments wherein R 4a is selected from —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, and —O—C(O)—N(R a )(R b ), R 5a is selected from hydrogen or (C 1 -C 5 )-alkyl. In certain embodiments, R 5a is fluoro. In certain embodiments, R 5a is fluoro. In certain embodiments, R
• R 5b is selected from hydrogen or (C 1 -C 5 )-alkyl. In certain embodiments wherein R 4b is selected from —OH, —O—(C 1 -C 5 )-alkyl, —O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, —O—C(O)-aryl, —O—C(O)-heteroaryl, —O—C(O)—O—(C 1 -C 5 )-alkyl, —O—C(O)—O-aryl, —O—C(O)—O-heteroaryl, and —O—C(O)—N(R a )(R b ), R 5b is selected from hydrogen or (C 1 -C 5 )-alkyl. In certain embodiments, R 5b is fluoro. In certain embodiments, R 5b is fluoro. In certain embodiments, R
• R 2 is —CH 2 —. In certain embodiments, R 2 is —C(O)—.
• R a is selected from H and C 1 -C 6 -alkyl. In certain embodiments, R a is selected from aryl, aralkyl, heteroaryl, and heteroaralkyl.
• R b is selected from H and C 1 -C 6 -alkyl. In certain embodiments, R b is selected from aryl, aralkyl, heteroaryl, and heteroaralkyl.
• R c is C 1 -C 6 -alkyl, aryl, or heteroaryl. In certain embodiments, R c is selected from aryl, aralkyl, heteroaryl, and heteroaralkyl.
• any hydrogen atom in R 3 is optionally and independently replaced by halo, (C 1 -C 5 )-alkyl, perfluoroalkyl, aryl, heteroaryl, hydroxy, or O—(C 1 -C 5 )-alkyl.
• R 3 is —CH 2 —O—CH 2
• any hydrogen atom in R 3 is optionally and independently replaced by halo, (C 1 -C 5 )-alkyl, perfluoroalkyl, aryl, heteroaryl, or O—(C 1 -C 5 )-alkyl.
• R 3 is selected from —(CH 2 ) n — and —CH 2 —O—CH 2 , wherein n is an integer from 1 to 3, and up to two hydrogen atoms in R 3 are optionally and independently replaced by (C 1 -C 5 )-alkyl.
• R 3 is selected from a carbocyclic ring, a heterocyclic ring, and CH 2 C(O)CH 2 , wherein n is an integer from 1 to 3; any hydrogen atom in R 3 is optionally and independently replaced by halo, (C 1 -C 5 )-alkyl, perfluoroalkyl, aryl, heteroaryl, hydroxy, or O—(C 1 -C 5 )-alkyl; and any two hydrogen atoms bound to a common carbon atom in R 3 are optionally taken together with the carbon atom to which they are bound to form a carbocyclic or heterocyclic ring.
• R 10a is hydrogen. In certain embodiments, R 10a is selected from (C 1 -C 5 )-alkyl, perfluoroalkyl, O—(C 1 -C 5 )-alkyl, aryl and heteroaryl, or R 10a is taken together with R 10b and the carbon atom to which they are bound to form a carbocyclic or heterocyclic ring.
• R 10b is hydrogen. In certain embodiments, R 10b is selected from (C 1 -C 5 )-alkyl, perfluoroalkyl, O—(C 1 -C 5 )-alkyl, aryl and heteroaryl, or R 10b is taken together with R 10a and the carbon atom to which they are bound to form a carbocyclic or heterocyclic ring.
• R 1 is —OR a . In certain embodiments, R 1 is selected from —N(R a )—SO 2 —R c and —N(R a )(R b ). In certain embodiments, R 1 is —N(R a )—SO 2 —R c . In certain embodiments, R 1 is selected from —OR a and —N(R a )(R b ). In certain embodiments, R 1 is —N(R a )(R b ). In certain embodiments, R 1 is selected from —OR a , and —N(R a )—SO 2 —R c .
• R 7 is hydrogen. In certain embodiments, R 7 is (C 1 -C 5 )-alkyl or two occurrences of R 7 may optionally be taken together with the carbons to which they are attached to form a 5- or 6-membered ring.
• X is —C ⁇ C— and R 4b is hydrogen.
• X is —C ⁇ C— and R 4a is hydrogen.
• X is —C ⁇ C—
• R 4a is fluoro
• R 5a is fluoro
• X is —C ⁇ C—
• R 4b is fluoro
• R 5b is fluoro
• X is —C ⁇ C—
• each of R 4a and R 4b is independently selected from —OH, —O—(C 1 -C 5 )-alkyl, O-aryl, O-heteroaryl, —O—C(O)—(C 1 -C 5 )-alkyl, O—C(O)-aryl, O—C(O)-heteroaryl, and —O—C(O)—N(R a )(R b ).
• X is —C ⁇ C— and R 2 is —CH 2 —.
• X is -(cyclopropyl)-, -(cyclobutyl)-, -(cyclopentyl)-, and -(cyclohexyl)-. In certain embodiments, X is -(cyclopropyl)-.
• X is —C(R 7 ) ⁇ C(R 7 )—.
• each of R a and R b is independently selected from H and C 1 -C 6 -alkyl;
• R c is C 1 -C 6 -alkyl;
• R 3 is selected from —(CH 2 ) n — and —CH 2 —O—CH 2 , wherein n is an integer from 1 to 3, and up to two hydrogen atoms in R 3 are optionally and independently replaced by (C 1 -C 5 )-alkyl;
• each of R 4a and R 4b is independently selected from hydrogen, halo, —OH, —O—(C 1 -C 5 )-alkyl; and each of R 10a and R 10b is hydrogen.
• each double bond is in an E-configuration. In certain embodiments, each double bond is in a Z-configuration. In certain embodiments, one double bond is in an E-configuration and one double bond is in a Z-configuration.
• any combination of the foregoing is contemplated herein.
• Those skilled in the art will recognize that all specific combinations of the individual possible residues of the variable regions of the compounds as disclosed herein, e.g., R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 10a , R 10b , R a , R b , R c , n and X, are within the scope of the present disclosure.
• any of the various particular recited embodiments for R 4a may be combined with any of the various particular recited embodiments of X.
• the compound optionally excluded from such compositions is selected from any one of:
• compositions of the present disclosure include an active agent, may be a compound of the formula V,
• R 1 is —OM
• M is a cation selected from ammonium, tetra-alkyl ammonium, Na, K, Mg, and Zn is optionally excluded from such compositions.
• R 2 and R 1 together are
• R 2 is —C(O)—.
• R 1 is +OR a , wherein R a is hydrogen or C 1 -C 6 -alkyl.
• R 3 is —(CH 2 ) n —, wherein n is 3.
• R 6 is —C ⁇ CH.
• R 5a is hydrogen.
• R 5b is hydrogen.
• R 10a is hydrogen.
• R 10b is hydrogen.
• R 2 is —C(O)—
• R 1 is +OR a , wherein R a is C 1 -C 6 -alkyl, R 3 is —(CH 2 ) n —, wherein n is 3, R 6 is —C ⁇ CH, R 5a is hydrogen, R 5b is hydrogen, R 10a is hydrogen, and R 10b is hydrogen.
• the compound is selected from any one of is optionally excluded from such compositions:
• an active agent optionally excluded from such compositions when compositions of the present disclosure include an active agent, may be a compound of formula VII,
• a compound of formula VII is represented by formula VIII,
• a compound of formula VII or VIII is represented by formula IX,
• the formulations as disclosed herein may be used to treat or prevent an ocular disease or disorder.
• Ocular diseases and disorders contemplated herein include anterior segment diseases and posterior segment diseases.
• Exemplary ocular diseases that may in certain embodiments be treated with formulations as disclosed herein include the following.
• Dry eye syndrome (DES, Chronic dry eye, Keratitis sicca; Xerophthalmia; Keratoconjunctivitis sicca) can be defined as a condition that includes a variety of disorders that result in a loss of, or altered composition of, the natural tear film, which maintains the surface of the eye. Without this tear film, vision is impaired and patients may suffer severe ocular discomfort.
• DES can be caused by excessive tear evaporation or by a reduction of tear production in the lacrimal gland, which is the site of tear production. Though the exact causes of this condition are unknown, there is evidence supporting the link between reduced tear production and inflammation of one or more components of the lacrimal apparatus.
• Currently available medications for DES are leaving substantial room for more effective and better tolerated products.
• DES may also be a manifestation of Sjogren's syndrome which is an autoimmune disorder in which the glands that produce tears and saliva are destroyed. This leads to dry mouth, decreased tearing, and other dry mucous membranes.
• Noninfectious uveitis is a chronic inflammatory, putative Th1/Th17-mediated autoimmune disease associated with substantial visual morbidity and is potentially blinding. Blindness from uveitis usually does not occur from a single inflammatory episode; rather, cumulative damage results from recurrent episodes of inflammation.
• the inflammatory sequalae resulting in vision loss may include one or more of cystoid macular edema, cataracts, vitreous debris, glaucoma, macular pathology (scarring and atrophy), optic neuropathy, and retinal detachment.
• Anterior uveitis occurs in the front of the eye and is the most common form of uveitis.
• Par planitis is an inflammation of the pars plana, a narrow area between the iris and the choroid. This condition occurs more frequently in young men, but is usually not associated with another disease.
• Posterior uveitis chondroitis
• Posterior uveitis affects primarily the choroid; the back portion of the uveal tract. If the retina is also involved, it is called chorioretinitis.
• Posterior uveitis may occur in association with an autoimmune disease, or follow a systemic infection. In posterior uveitis, inflammation can last from months to years and may cause permanent vision damage, even with treatment.
• Uveitis can cause vision impairment, ocular pain, and loss of vision. It is estimated that about 10% of new cases of blindness in the U.S. are caused by uveitis. Approximately 300,000 people suffer from uveitis in the U.S. alone, the majority of whom are affected by anterior uveitis.
• the only therapeutic class approved by the FDA for treatment of uveitis is corticosteroids, which are noted for multiple side effects, such as hypertension, hyperglycemia, and hypercholesterolemia, and in the eye, glaucoma and cataract formation.
• Conjunctivitis pink eye
• Keratitis is an inflammation of the cornea (clear portion in the front of the eye). Keratitis can be caused by an infection (bacterial, fungal, viral, parasite, etc.) or a non-infectious agent (e.g., certain types of auto-immune diseases are associated with a variety of non-infectious keratitises).
• an infection bacterial, fungal, viral, parasite, etc.
• a non-infectious agent e.g., certain types of auto-immune diseases are associated with a variety of non-infectious keratitises.
• Keratoconjunctivitis refers to an inflammation of the cornea and conjunctiva.
• Vernal keratoconjunctivitis is a recurrent ocular inflammatory disease characterized by hard, elevated, cobblestone like bumps on the upper eyelid. There may also be swellings and thickening of the conjunctiva.
• the conjunctiva is the outermost membrane which lines the eyelids as well as the exposed parts of the eye, except for the cornea.
• Atopic keratoconjunctivitis is the result of a condition called atopy.
• Atopy is a genetic condition whereby the immune system produces higher than normal antibodies in response to a given allergen.
• Systemic immune mediated diseases such as cicatrizing conjunctivitis and other autoimmune disorders of the ocular surface represent a clinically heterogeneous group of conditions where acute and chronic autoreactive mechanisms can cause significant damage to the eye.
• cicatrization can ensue, leading to significant mechanical alterations as a result of the fibrosis.
• These conditions though generally infrequent, can be the cause of profound pathology and visual disability.
• Blepharitis is a common condition that causes inflammation of the eyelids.
• Scleritis is a serious inflammatory disease that affects the white outer coating of the eye, known as the sclera.
• Age-related macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. AMD affects the macula, which is located at the center of the retina. AMD occurs in two forms: wet and dry.
• Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula. These new blood vessels tend to be very fragile and often leak blood and fluid. The blood and fluid raise the macula from its normal place at the back of the eye. Damage to the macula occurs rapidly.
• Dry AMD occurs when the light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.
• Diabetic retinopathy is a complication of diabetes that results from damage to the blood vessels of the light-sensitive tissue at the back of the eye (the retina). At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, however, diabetic retinopathy can result in blindness.
• Diabetic macular edema DME is the swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula.
• Ocular neovascularization is the abnormal or excessive formation of blood vessels in the eye. Ocular neovascularization has been shown in diabetic retinopathy and age-related macular degeneration (AMD).
• AMD age-related macular degeneration
• PVR Proliferative vitreoretinopathy
• CMV cytomegalovirus
• HAV disease
• organ or bone marrow transplant or chemotherapy
• CMV virus can cause damage and disease to the eye and the rest of the body.
• CMV affects the eye in about 30% of the cases by causing damage to the retina. This is called CMV retinitis.
• Optic neuritis occurs when the optic nerve becomes inflamed and the myelin sheath becomes damaged or is destroyed. Nerve damage that occurs in the section of the optic nerve located behind the eye, is called retrobulbar neuritis, which is another term sometimes used for optic neuritis.
• epiretinal membrane is a scar-tissue like membrane that forms over the macula. It typically progresses slowly and affects central vision by causing blurring and distortion. As it progresses, the pulling of the membrane on the macula may cause swelling.
• the compositions can be used for preventing transplant rejection of, for example, corneal allografts following transplantation. It is well known that in inflammation T-lymphocytes play a critical role in mediating rejection of foreign tissues. Prevention of rejection is of paramount importance in maintaining the health of transplanted corneas. Rejection may occur in any of the layers comprising the cornea, for example, the corneal epithelium, the corneal stroma or the corneal endothelium. The functioning of the cornea can be compromised following endothelial rejection. The endothelial layer serves to maintain the cornea in a compact state, acting as a pump by removing water from the corneal stroma.
• compositions of the present disclosure can be used for the prevention of rejection following corneal allograft transplantation.
• compositions of the present disclosure may also contain other components such as, but not limited to, additives, adjuvants, buffers, tonicity agents, bioadhesive polymers, and preservatives.
• the mixtures are preferably formulated at about pH 5 to about pH 8. This pH range may be achieved by the addition of buffers to the composition as described in the examples.
• the pH range in the composition in a formulation is about pH 6.6 to about pH 7.0.
• compositions of the present disclosure may be buffered by any common buffer system such as phosphate, borate, acetate, citrate, carbonate and borate-polyol complexes, with the pH and osmolality adjusted in accordance with well-known techniques to proper physiological values.
• the mixed micellar compositions of the present disclosure are stable in buffered aqueous solution. That is, there is no adverse interaction between the buffer and any other component that would cause the compositions to be unstable.
• Tonicity agents include, for example, mannitol, sodium chloride, xylitol, etc. These tonicity agents may be used to adjust the osmolality of the compositions. In one aspect, the osmolality of the formulation is adjusted to be in the range of about 250 to about 350 mOsmol/kg. In a preferred aspect, the osmolality of the formulation is adjusted to between about 280 to about 300 mOsmol/kg.
• compositions of the present disclosure can be included in the compositions of the present disclosure.
• Pharmaceutical additives can be added to increase the efficacy or potency of other ingredients in the composition.
• a pharmaceutical additive can be added to a composition of the present disclosure to improve the stability of the calcineurin inhibitor or mTOR inhibitor, to adjust the osmolality of the composition, to adjust the viscosity of the composition, or for another reason, such as effecting drug delivery.
• Non-limiting examples of pharmaceutical additives of the present disclosure include sugars, such as, trehalose, mannose, D-galactose, and lactose.
• the sugars can be incorporated into a composition prior to hydrating the thin film (i.e., internally). In another embodiment, the sugars can be incorporated into a composition during the hydration step (i.e., externally) (see Example 17).
• an aqueous, clear, mixed micellar solution of the present disclosure includes additives such as sugars.
• compositions of the present disclosure further comprise one or more bioadhesive polymers.
• Bioadhesion refers to the ability of certain synthetic and biological macromolecules and hydrocolloids to adhere to biological tissues. Bioadhesion is a complex phenomenon, depending in part upon the properties of polymers, biological tissue, and the surrounding environment. Several factors have been found to contribute to a polymer's bioadhesive capacity: the presence of functional groups able to form hydrogen bridges (—OH, COOH), the presence and strength of anionic charges, sufficient elasticity for the polymeric chains to interpenetrate the mucous layer, and high molecular weight. Bioadhesion systems have been used in dentistry, orthopedics, ophthalmology, and in surgical applications.
• bioadhesive materials in other areas such as soft tissue-based artificial replacements, and controlled release systems for local release of bioactive agents.
• Such applications include systems for release of drugs in the buccal or nasal cavity, and for intestinal or rectal administration.
• a composition of the present disclosure includes at least one bioadhesive polymer.
• the bioadhesive polymer can enhance the viscosity of the composition and thereby increase residence time in the eye.
• Bioadhesive polymers of the present disclosure include, for example, carboxylic polymers like Carbopol® (carbomers), Noveon® (polycarbophils), cellulose derivatives including alkyl and hydroxyalkyl cellulose like methylcellulose, hydroxypropylcellulose, carboxymethylcellulose, gums like locust beam, xanthan, agarose, karaya, guar, and other polymers including but not limited to polyvinyl alcohol, polyvinyl pyrollidone, polyethylene glycol, Pluronic® (Poloxamers), tragacanth, and hyaluronic acid; phase-transition polymers for providing sustained and controlled delivery of enclosed medicaments to the eye (e.g., alginic acid, carrageenans (e.g.
• compositions of the present disclosure further comprise at least one hydrophilic polymer excipient selected from, for example, PVP-K-30, PVP-K-90, HPMC, HEC, and polycarbophil.
• the polymer excipient is selected from PVP-K-90, PVP-K-30 or HPMC.
• the polymer excipient is selected from PVP-K-90 or PVP-K-30.
• the compositions may optionally be preserved with any of many well-known preservatives, including benzyl alcohol with/without EDTA, benzalkonium chloride, chlorhexidine, Cosmocil® CQ, or Dowicil® 200.
• preservatives may in some embodiments not be necessary or desirable in formulations included in single use containers.
• the ophthalmic compositions can be administered topically to the eye as biocompatible, aqueous, clear mixed micellar solutions.
• the compositions have the drugs incorporated and/or encapsulated in micelles which are dispersed in an aqueous medium.
• a formulation comprising a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol
• a volume of 500 microliter distilled deionized water is added to this mixture to obtain a total volume of 1000 microliter (1 milliliter).
• Addition of water to the drug polymer mixture in organic solvent should spontaneously generate micelles thereby entrapping the pharmaceutical active agent in the hydrophobic core of mixed nanomicelles.
• the mixture is transferred to a dialysis bag (molecular weight cut off 1000) and transferred to a beaker containing one liter of distilled deionized water. Beaker and the contents are protected from sunlight by covering with aluminum foil and are kept under slow constant stirring at room temperature. Dialysis of the mixture is carried over a period of 24 h to remove the water soluble organic solvent, propylene glycol, from the mixture. Water in the dialysis chamber is changed at predetermined time points: 1 h, 2 h, 4 h, 6 h, 12 h and 24 h.
• the contents of the dialysis bag are carefully transferred to a 15-mL centrifuge tube and formulations are subjected to sonication in water bath (time range from 0 min to 5 min).
• the final volume is made up with 2 ⁇ phosphate buffer saline and adjusted pH of the formulation to 6.5 ⁇ 0.1.
• the resultant formulation is filtered with 0.22 micrometer nylon filter to remove any foreign particulate matter.
• the prepared formulations are subjected to various tests such as entrapment efficiency, loading efficiency, mixed nanomicellar size and polydispersity index.
• the formulation size and polydispersity index are determined with Zetasizer, Malvern Instruments, NJ. In brief, approximately 1 mL of each formulation is transferred to a cuvette and placed in the instrument. A laser beam of light is used to determine the mixed nanomicellar size. The results of the size are summarized in Table 2.
• formulations are vortex mixed for homogeneity and 1 mL is transferred to a fresh (1.5 mL) eppendorf tube. Each formulation is lyophilized to obtain a solid at the bottom of eppendorf tube. The obtained solid is suspended in 1 mL of organic solvent (diethyl ether) to generate reverse micelles and release the drug into the external organic solvent. The organic solvent is evaporated overnight in speed vacuum.
• organic solvent diethyl ether
• Entrapment efficiency (amount of drug quantified in MNF/Amount of drug added in the MNF) ⁇ 100
• RP-HPLC reversed phase high performance liquid chromatography
• the mobile phase is comprised of methanol (MeOH), water and trifluoroacetic acid (TFA) (70:30:0.05% v/v) which is set at a flow rate of 0.5 mL/min. Detection wavelength is set at 272 nm. The sample tray temperature is maintained at 4° C.
• Calibration curve (0.5 to 5 ⁇ g/mL) for active compound is prepared by making appropriate dilutions from the stock solution in 2-propanol. An injection volume of 10 ⁇ l is injected into the HPLC column for analysis. All the standards and samples prepared are stored at 4° C. before and during the analysis.
• step one active compound, HCO-60 and octoxynol-40 are dissolved separately in 0.3 mL of ethyl acetate. These three solutions are mixed together in 15-mL centrifuge tube. The resultant mixture is vortexed to obtain a homogenous solution. Ethyl acetate solvent is removed with speed vacuum to obtain a solid thin film. The residue is kept overnight under high vacuum at room temperature to remove residual organic solvent.
• step two the resultant thin film is hydrated with 1 mL of double distilled deionized water by vortexing the solution.
• the rehydrated formulation is suspended in 2 ⁇ phosphate buffer solution, (pH 6.5). It is filtered through 0.2 ⁇ m nylon filter membrane to remove the unentrapped drug aggregates and other foreign particulates.
• the entrapment of active compound is determined by RP-HPLC following disruption of the micelles and solubilization of 1001 in the diluent (2-propanol) as described below.
• the prepared formulations are subjected to various tests such as entrapment efficiency, loading efficiency, mixed nanomicellar size and polydispersity index according to the methods described in Example 1.
• Weight percent of drug loaded into MNF is determined following the method for entrapment efficiency. Size and polydispersity index of the formulations is determined with Malvern zetasizer as described above. The results obtained are summarized in Table 2 below. The formulations appear clear and have small size and narrow size distribution.
• HCO-60 hydrogenated castor oil-60
• RBF round bottom flask
• the neck of the round bottom flask is closed with aluminum foil, sealed with parafilm and transferred to a water bath set at 40° C.
• the round bottom flask is left overnight in a water bath to liquefy/melt the HCO-60.
• octoxynol-40 is diluted 100 fold and allowed to equilibrate at 40° C. for 1 h in a water bath.
• active compound (as a neat oil) is allowed to equilibrate at 40° C. in the water bath for 1 h.
• phosphate buffer was previously prepared and the pH was adjusted to 5.5.
• the volume of the formulation is made up to 5 mL with the 2 ⁇ phosphate buffer saline.
• the prepared formulation is filtered with 0.2 ⁇ m nylon filter and stored at 4° C.
• the prepared formulations are subjected to various tests such as entrapment efficiency, loading efficiency, mixed nanomicellar size and polydispersity index according to the methods described in Example 1.
• step 1 HCO-40 or HCO-60, 150 mg, is thermostated at 40° C. in a water bath to melt and result in a clear thick viscous liquid.
• active compound ⁇ 20 mg
• step 2 active compound ( ⁇ 20 mg)
• step 3 active compound ( ⁇ 20 mg)
• step 4 solidify the viscous liquid of HCO-40
• the mixture is stored at 4° C. (in refrigerator).
• step 2 the pellet and/or viscous liquid is allowed to reach room temperature under natural conditions.
• the pellet and/or viscous liquid is thermostated in a water bath at 40° C. and resuspended in 2.0 mL of distilled water (thermostated at 40° C.) under constant stirring. This results in spontaneous development of a clear aqueous solution of 0.4% active compound MNF.
• This aqueous solution is allowed to reach room temperature, under natural conditions.
• the pH of the solution is adjusted to 5.5 and the volume is made up with 2 ⁇ phosphate buffer saline (pH 5.5) containing octoxynol-40 (0.01 wt %) and PVP-K-90 (1.2 wt %).
• the formulation is filtered through 0.2 ⁇ m nylon filter to remove any foreign material and obtain a clear homogenous aqueous active-containing formulation.
• HCO-40 or HCO-60 at 40° C. can be used to entrap active compound.
• the polymer and the drug mixture remain in a viscous liquid state.
• HCO-60 mixture solidifies and develops a waxy solid.
• This waxy solid when thermostated at 40° C., helps in resuspending the formulation in distilled water to spontaneously develop active compound-containing MNF.
• Similar observation and results are obtained with HCO-40 viscous liquid.
• the viscosity of the mixture appears to be improved at lower temperatures (4° C.). Therefore, it appears to stick to the walls of the container as thick viscous liquid. Upon allowing to reach back to room temperature the viscosity appears to be reduced and the mixture retains its flow back.
• the waxy solid developed with HCO-60 and active compound mixture may be helpful to protect the drug and prevent drug degradation with a surface blanket of an inert gas.
• the other polymer (HCO-40) did not result in development of waxy solid at room temperature or at low refrigerated conditions (4° C.) when used up to approx. 3.0 wt %.
• HCO-60 can be used to entrap active compound with Hot Melt method.
• HCO-40 does not develop waxy solid at higher weight percent (3.0%) under the conditions of this study.
• HCO-60 develops waxy solid at 2.0 wt %.
• This method has unique advantages of being an easy and fast method that avoids the use of organic solvent in the preparation of MNF. Also, the method of preparation is easy and fast.
• the waxy solid developed in stage 1 may be helpful in preventing the drug degradation and help the drug to stay in waxy solid state at room temperatures with a blanket of inert gas.
• Qualitative proton NMR studies show that drug is not freely available when resuspended in aqueous solution. On the other hand, when the same formulation is resuspended in organic solvent, CDCl 3 , drug peaks are clearly evident indicating the presence of drug in the outer organic solvent environment due to the formation.
• MNF formulation of active agent is prepared by solvent evaporation method in two steps: 1. Preparation of basic formulation and 2. rehydration.
• step one active agent, HCO-40 and octoxynol-40 are dissolved separately in 0.5 mL of ethanol aliquots. These three solutions are mixed together in a round bottom flask. The resultant mixture is stirred to obtain a homogenous solution. Ethanol solvent is removed by high speed vacuum evaporation overnight to obtain a solid thin film.
• step two the resultant thin film is hydrated with 2.0 mL of double distilled deionized water and resuspended with stirring overnight.
• the rehydrated formulation is pH adjusted and the volume is made up with 2 ⁇ phosphate buffer solution, (pH 6.8). Further the formulation is filtered through 0.2 ⁇ m nylon filter membrane to remove the unentrapped drug aggregates and other foreign particulates.
• MNF formulation of active agent is prepared by the water method.
• One mL of double distilled deionized water is heated to 60° C. in a round bottom flask. This heated water is kept under stirring.
• HCO-40 is added to the heated water and allowed to dissolve under constant stirring.
• Octoxynol-40 is then added to this mixture and allowed to dissolve.
• phosphates, sodium chloride and CsA are blended by hand shaking for a few minutes. Under stirring conditions, the phosphates/CsA/sodium chloride blend is added to the solution of HCO-40 and octoxynol-40 to disperse the drug. This mixture is allowed to cool to room temperature while stirring and check for complete dissolution of drug.
• PVP K 90 solution is separately prepared using the remaining 1 mL double distilled deionized water. This PVP K 90 solution is added to the solution of polymer/surfactant/drug/phosphate/sodium chloride. Water is added to make up the final volume. Then the formulation is filtered through 0.2 ⁇ m nylon membrane to remove the drug aggregates and other foreign particulates.
• Healthy young adult New Zealand albino rabbits (3-4 Kg) are used for the study of the local tolerability of formulations as described herein, for example a formulation of Examples 1-5.
• One drop (approximately 30 ⁇ mu ⁇ L) of saline is placed in one eye and a drop of formulation is placed in the other eye of the rabbit. Both eyes of each animal are examined by a veterinary ophthalmologist using a hand-held slit lamp and indirect ophthalmoscope.
• Both control and test eyes are graded according to conjunctival congestion, swelling, and discharge, aqueous flare, iris light reflex and involvement, corneal cloudiness severity and area, pannus, fluorescein examination and lens opacity using the Hackett/McDonald scoring system (see, for example, Hackett, R. B. and McDonald, T. O. Ophthalmic Toxicology and Assessing Ocular Irritation. Dermatoxicology, 5.sup.th Edition. Ed. F. N. Marzulli and H. I. Maibach. Washington, D.C.: Hemisphere Publishing Corporation. 1996; 299-305 and 557-566.).
• the crystalline lens is observed with the aid of the slit-lamp biomicroscope, and the location of lenticular opacity is discerned by direct and retro illumination.
• the location of lenticular opacities are arbitrarily divided into the following lenticular regions beginning with the anterior capsule: Anterior subcapsular, Anterior cortical Nuclear Posterior cortical, Posterior subcapsular, Posterior capsular.
• the lens is evaluated routinely during ocular evaluations and graded as either 0 (normal) or 1 (abnormal). The presence of lenticular opacities are described and the location noted.
• NZW rabbits are used in a single dose (SD) and 7-day repeat dose (RD) studies.
• DB rabbits will be used in a single dose study).
• Animals are either untreated (controls) or given a single or a daily topical ocular dose for 7 days (0.05 wt %, 0.2 wt % or 0.5 wt % in a mixed micellar formulation to one or both eyes). Blood and ocular tissue concentrations are assessed.
• the concentration of drug is in tissues in the front of the eye (cornea, conjunctiva, sclera) and at the back of the eye (retina, optic nerve) but minimal in the middle of the eye (aqueous and vitreous humor), suggesting transport of the drug by a mechanism other than passive transport through the eye.
• the high drug levels achieved at the back of the eye make topical administration of the compositions of the present disclosure feasible for the treatment of diseases of the back-of-the-eye (e.g., retinal, diseases involving optic nerve such as glaucoma). Very high levels, especially in target tissues such as lachrymal gland, will be shown with the compositions of the present disclosure.
• Mixed nanomicellar formulations according to Examples 1-5 are administered to a patient having dry eye at a concentration of between 0.05% and 0.2% b.i.d. over a period of 1 month to 1 year or more.
• Mixed nanomicellar formulations according to Examples 1-5 are administered to a patient having proliferative diabetic retinopathy at a concentration of between 0.2 wt % to 0.5 wt % b.i.d. over a period of 1 month to 1 year or more.
• One drop (approximately 35 ⁇ L) of study drug is applied o.d. 4 ⁇ /day at two hour intervals for 5 days.
• One drop of BSS is applied to the contralateral eye.
• the tolerance parameters evaluated are: physical examination (acclimation study release); viability (daily); clinical observations (daily); hackett-McDonald Ocular Irritation scores (pre-dose baseline data for each rabbit and then a pre-dose [prior to first daily dose] each day and then 30 min after last dose daily, intraocular pressure (IOP) pre-dose baseline data for each rabbit and then 30 minutes after the evening examinations each day, electroretinography (ERG) pre-dose-(pre-study) baseline data for each rabbit and then one hour after the last treatment, and ocular histopathology at euthanasia.
• IOP intraocular pressure
• ERG electroretinography
• Mean cumulative Strett-McDonald ocular irritation scores demonstrate very minimal scores for both BSS-treated left eyes and cyclosporine treated right eyes throughout the study, both for pre-treatment and post-treatment examination times. Mean cumulative inflammatory scores of less than 2 are observed in eyes treated with the TA, placebo, and BSS. These clinical scores represent mild conjunctival hyperemia (redness) and swelling. However, there are no significant differences in mean cumulative Linett-McDonald ocular irritation scores between the groups, suggesting no difference in irritation from topical application of 0.1% CsA in HCO-40, the HCO-40 placebo, and BSS.
• Samples of selected ocular tissues are collected 1 hour following the last dose on Day 5 from all two rabbits that received 0.1% active agent with HCO-40 (OD), and BSS (OS), and from one rabbit (No. 21) that received placebo HCO-40 formulation (OD) and BSS (OS).
• the samples are assayed for active agent by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
• the internal standard is d 4 -active agent.
• the established analytical ranges for active agent are 0.100-100 ng/mL for whole blood, and 2.00-2000 ng/mL for aqueous humor and vitreous humor.
• the analytical ranges for the solid tissues are 0.125-30 ng (low range) and 1.00-2500 ng (high range).
• the results of the solid tissue analyses are converted to ng/g by correcting for the amount of tissue analyzed.
• Concentrations of active agent in ocular tissues collected 1 hour following the last dose on Day-5 are summarized in Table 6.
• the highest average active agent concentrations in the treated eye are observed in cornea (7805 ng/g), followed by conjunctiva (2125 ng/g), sclera (720 ng/g), iris-ciliary body (204 ng/g), and aqueous humor (134 ng/mL).
• the lowest active agent concentrations are observed in the lens (68.6 ng/g), retina/choroid (54 ng/g), and vitreous humor ( ⁇ 8 ng/mL).
• Active agent concentrations in the collateral eye treated with BSS are quite low suggesting minimal systemic transfer of drug.
• the ocular tissue concentrations for the 0.1% active agent formulation observed in this study are generally higher than the C max values following repeat dose administration (bid for 7 days) of an Allergan 0.2% 3H cyclosporine A formulation to rabbits (see Acheampong A A, Shackleton M, Tang-Liu D, Ding S, Stern M E, Decker R Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs; Current Eye Research 18(2); 1999; pp 91-103).
• the tolerance parameters evaluated are: physical examination (acclimation study release); viability (daily); clinical observations (daily); hackett-McDonald Ocular Irritation scores (pre-dose baseline data for each rabbit and then a pre-dose [prior to first daily dose] each day and then 30 min after last dose daily, intraocular pressure (IOP) pre-dose baseline data for each rabbit and then 30 minutes after the evening examinations each day, electroretinography (ERG) pre-dose-(pre-study) baseline data for each rabbit and then one hour after the last treatment, and ocular histopathology at euthanasia.
• IOP intraocular pressure
• ERG electroretinography
• RX-10045 0.15% RX-10045 (0.1% in HCO-40 Placebo Components percentage percentage RX-10045 0.1% 0 Hydrogenated Castor 1.0% 1.0% Oil-40 Octoxynol-40 0.05% 0.05% Sodium chloride 0.10% 0.10% PVP-K90 0.60% 0.60% Disodium EDTA 0.05% 0.05% Benzalkonium 0.003% 0.003% chloride Sodium Phosphate ⁇ 0.4% ⁇ 0.4% buffer pH 5.5 5.5
• Formulation Composition RX-10045 0.1% RX-10045 (0.15%) in HCO-60 Placebo Components percentage Percentage RX-10045 0.15% 0 Hydrogenated Castor 1.0% 1.0% Oil-40 Octoxynol-40 0.05% 0.05% Sodium chloride 0.10% 0.10% PVP-K90 0.60% 0.60% Disodium EDTA 0.05% 0.05% Benzalkonium 0.003% 0.003% chloride Sodium Phosphate ⁇ 0.4% ⁇ 0.4% buffer pH 5.5 5.5
• Cumulative Strett-McDonald ocular irritation scores demonstrate very minimal mean values for both BSS-treated left eyes and test-article treated right eyes throughout the study, both for pre-treatment and post-treatment examination times. There are no significant differences in mean cumulative Hackett-McDonald ocular irritation scores between the groups (Table 8). The observed ocular irritation is interpreted as minimal and transient in all groups.
• Selected ocular fluids/tissues (aqueous humor, vitreous humor, conjunctiva, cornea, iris-ciliary body, lens, retina/choroid, and sclera) collected from two rabbits each in the active agent (0.15% in HCO-60, 0.1% in HCO-40) treatment groups, and from one rabbit in each of the matching placebo groups, are assayed for active compound by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Warfarin-d 5 and 5-HDA are used as internal standards for the analysis of RX-10045 and its active metabolite, RX-10008, respectively, in aqueous humor and vitreous humor.
• LC-MS/MS liquid chromatography-tandem mass spectrometry
• warfarin-d5 and phenyl acetic acid-d5 are used as the internal standards for compound 1001 and RX-10008, respectively.
• the analytical range for the solid tissues is 0.125-100 ng.
• the results of the solid tissue analyses are converted to ng/g by correcting for the amount of tissue analyzed.
• RX-10008 tissue concentrations is presented in Table 9. The highest concentrations of RX-10008 are found in the cornea, followed by the iris-ciliary body, conjunctiva, and sclera. There are also relatively high concentrations of RX-10008 in the aqueous humor. Lower amounts are found in the retina/choroid and lens. The lowest levels of RX-10008 are found in the vitreous humor.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Ophthalmology & Optometry (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=58695926

Family Applications (2)

Family Applications After (1)

Country Status (8)

Families Citing this family (2)

Citations (1)

Family Cites Families (16)

• 2016
  • 2016-11-03 EP EP16864797.2A patent/EP3373976B1/en active Active
  • 2016-11-03 DK DK16864797.2T patent/DK3373976T3/da active
  • 2016-11-03 FI FIEP16864797.2T patent/FI3373976T3/fi active
  • 2016-11-03 PT PT168647972T patent/PT3373976T/pt unknown
  • 2016-11-03 WO PCT/US2016/060391 patent/WO2017083167A1/en active Application Filing
  • 2016-11-03 AU AU2016351588A patent/AU2016351588A1/en not_active Abandoned
  • 2016-11-03 US US15/772,779 patent/US20190231885A1/en not_active Abandoned
  • 2016-11-03 EP EP23219654.3A patent/EP4364810A2/en active Pending
  • 2016-11-03 JP JP2018543272A patent/JP2018532809A/ja active Pending
• 2021
  • 2021-03-12 US US17/200,454 patent/US20210268114A1/en active Pending
• 2022
  • 2022-11-04 JP JP2022177207A patent/JP2023012533A/ja active Pending

Patent Citations (1)

Also Published As

Similar Documents

Legal Events